Efficacy News and Research

RSS

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.

19 May 2011

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study.

19 May 2011

Alemtuzumab as effective as other more expensive immune suppressants for kidney transplants

In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug - at one-half to one-fifth the price - is as safe and effective as the other two, according to a paper published by University of Alabama at Birmingham researchers in the May 19, 2011, issue of the New England Journal of Medicine.

19 May 2011

Face masks worn by TB patients could cut transmission rates to non-infected patients

Face masks worn by patients infected with tuberculosis (TB) may be able to significantly cut transmission rates to non-infected patients, according to a new study by researchers from the U.S. and South Africa. The study was conducted in a specialized airborne infections research facility in South Africa, which was designed to allow study of methods to control the spread of TB.

18 May 2011

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Routine Aedes aegypti mosquito control programs less expensive than ITC to fight dengue

The first-known study comparing costs of routine Aedes aegypti mosquito control programs and insecticide-treated curtains reveals that the cost of RACP is substantially lower than that of ITC implementation for dengue control and prevention.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

$Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery$

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

Avedro, Inc. today announced the completion of all one-year follow-up visits for patients enrolled in its two multi-center Phase III studies evaluating the safety and efficacy of corneal collagen cross-linking for the treatment of progressive keratoconus and ectasia following refractive surgery.

18 May 2011

Efficacy News and Research

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

Alemtuzumab as effective as other more expensive immune suppressants for kidney transplants

Face masks worn by TB patients could cut transmission rates to non-infected patients

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Routine Aedes aegypti mosquito control programs less expensive than ITC to fight dengue

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Avedro completes two Phase III corneal cross-linking studies in keratoconus, ectasia post-refractive surgery

Teva, ERYtech Pharma sign long term distribution agreement for Graspa in Israel

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

New avenue for treating breast cancer

Study: Sleep problems more common among urban minority children than previously thought

Medtronic to present clinical trial data of IN.PACT drug-eluting balloon technology at EuroPCR meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News